Capecitabine-Induced Subacute Cutaneous Lupus Erythematosus in a Patient with Systemic Lupus Erythematosus

Main Article Content


capecitabine, systemic lupus erythematosus, drug-induced subacute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus


Capecitabine is a fluoropyrimidine chemotherapy prodrug of 5-fluorouracil (5-FU) used in the treatment of metastatic breast and colorectal cancers. Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is a rare side effect of capecitabine therapy, with eight cases previously reported. We report a case of DI-SCLE in a patient with a documented history of systemic lupus erythematosus (SLE). This is the second documented case of DI-SCLE in a patient with a past medical history of SLE, and provides evidence that there may be an increased risk of DI-SCLE in these patients. Further research should examine whether patients with SLE are at greater risk for this adverse event. 


1. Ko JH, Hsieh CI, Chou CY, Wang KH. Capecitabine-induced subacute cutaneous lupus erythematosus: report of a case with positive rechallenge test. The Journal of dermatology. 2013;40(11):939-940.

2. Kindem S, Llombart B, Requena C, et al. Subacute cutaneous lupus erythematosus after treatment with capecitabine. The Journal of dermatology. 2013;40(1):75-76.

3. Weger W, Kranke B, Gerger A, Salmhofer W, Aberer E. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol. 2008;59(2 Suppl 1):S4-6.

4. Li Z, Jiang N, Xu Y. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy. The Australasian journal of dermatology. 2016;57(1):e14-16.

5. Kim WI, Kim JM, Kim GW, et al. Subacute cutaneous lupus erythematosus induced by capecitabine: 5-FU was innocent. Journal of the European Academy of Dermatology and Venereology : JEADV. 2016;30(11):e163-e164.

6. Fongue J, Meunier B, Lardet D, et al. Capecitabine-induced subacute cutaneous lupus: a case report. Annales de dermatologie et de venereologie. 2014;141(10):593-597.

7. Fernandes NF, Rosenbach M, Elenitsas R, Kist JM. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy. Archives of dermatology. 2009;145(3):340-341.

8. Floristan U, Feltes RA, Sendagorta E, et al. Subacute cutaneous lupus erythematosus induced by capecitabine. Clinical and experimental dermatology. 2009;34(7):e328-329.

9. Marchetti MA, Noland MM, Dillon PM, Greer KE. Taxane associated subacute cutaneous lupus erythematosus. Dermatology online journal. 2013;19(8):19259.

10. Lebeau S, Tambe S, Sallam MA, et al. Docetaxel-induced relapse of subacute cutaneous lupus erythematosus and chilblain lupus. Journal der Deutschen Dermatologischen Gesellschaft : JDDG. 2013;11(9):871-874.

11. Novak GV, Marques M, Balbi V, et al. Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. Autoimmunity reviews. 2017;16(2):132-135.

12. Adachi A, Nagai H, Horikawa T. Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. Dermatology (Basel, Switzerland). 2007;214(1):85-88.